Savara Inc. Reports $40.2 Million Net Loss in Q2 2026, Progresses with MOLBREEVI Development

Savara Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $40.2 million, compared to a net loss of $30.4 million for the same period in 2025. For the first half of 2026, the company recorded a net loss of $77.5 million, up from $57.0 million in the prior year. The increase in losses is attributed to higher operating expenses, which totaled $41.0 million for the quarter and $80.0 million for the six months, reflecting a year-over-year increase of 29.5% and 33.5%, respectively. Research and development expenses rose to $22.0 million for the quarter, primarily due to increased personnel costs, while general and administrative expenses surged by 78.2% to $19.0 million, driven by higher stock-based compensation and headcount growth.

Savara's total assets decreased to $192.1 million as of June 30, 2026, down from $253.4 million at the end of 2025. The decline in assets was primarily due to a reduction in short-term investments, which fell to $131.2 million from $202.5 million. The company's cash and cash equivalents increased to $41.8 million, up from $33.2 million at the end of 2025. The accumulated deficit also widened to approximately $685.6 million, reflecting the ongoing investment in the development of its sole product candidate, MOLBREEVI, an inhaled biologic for autoimmune pulmonary alveolar proteinosis.

In terms of strategic developments, Savara has made significant progress with its clinical program for MOLBREEVI. The company announced positive topline results from the Phase 3 IMPALA-2 trial and has submitted a Biologics License Application (BLA) to the FDA, which has granted Priority Review. The European Medicines Agency (EMA) has also validated the marketing authorization application for MOLBREEVI. These regulatory advancements are critical as Savara prepares for potential commercialization, although the company has not yet generated any product revenue.

Operationally, Savara's workforce has expanded as it builds out its commercial team in anticipation of a product launch. The company reported an increase in employee headcount, which contributed to the rise in general and administrative expenses. As of June 30, 2026, Savara had approximately 205.4 million shares outstanding, reflecting ongoing stock option exercises and other equity activities. The company continues to focus on its clinical development and regulatory approval processes, which are expected to incur significant costs in the coming years.

Looking ahead, Savara acknowledges the need for additional capital to support its ongoing operations and product development. The company has access to a loan facility of up to $105 million under the Hercules Loan Agreement, which it may draw upon contingent on achieving regulatory milestones. However, the company cautions that failure to secure necessary funding could adversely impact its ability to continue its development efforts and achieve commercialization of MOLBREEVI.